GlobeNewswire·Oct 13, 2026, 7:30 AM ET

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

Intellia Therapeutics appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer effective October 26, 2026.
Dr. Marantz brings over 25 years of biopharmaceutical experience, including leading the U.S. approval of ISEMBYLD at Scholar Rock.
In her new role, she will lead Intellia's translational, development, regulatory, and medical affairs functions.
Her appointment supports Intellia's efforts to commercialize lonvoguran ziclumeran (lonvo-z), advance Phase 3 trials for nexiguran ziclumeran (nex-z) in transthyretin amyloidosis, and expand its pipeline.
Dr. Marantz previously held senior leadership positions at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals.
She holds an MBA from the University of California at Berkeley, a Ph.D. in Biochemistry and Molecular Biology from the Medical University of South Carolina, and medical training from Tongji Medical College.
Dr. Marantz currently serves on the Board of Directors for Arcturus Therapeutics, Inc.